Basket | Login


SS2 EPAD, an innovative private-public partnership for the prevention of Alzheimer's dementia

Detailed programme, abstracts and presentations

SS2. EPAD, an innovative private-public partnership for the prevention of Alzheimer’s dementia

BADGER Shirlene, LOVESTONE Simon, VAN der GEYTEN Serge

There is an urgent need for new treatments for Alzheimer’s disease. The number of people affected worldwide is expected to reach over 100 million by 2050, yet despite intensive efforts over many years, there is still no cure for Alzheimer’s and little in the way of treatments. Memantine, the last drug for Alzheimer’s disease was approved over 10 years ago.

Today, research increasingly focuses on ways to prevent the onset of Alzheimer’s disease or the progression to Alzheimer’s dementia in the first place. The EPAD project is pioneering a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s dementia. Using an “adaptive” trial design should deliver better results faster and at lower cost.

This innovative trial design has already proven effective for testing new treatments for breast cancer. The EPAD project is pioneering this approach in Alzheimer’s disease. By adopting this approach, the project expects to be able to identify ineffective medicines earlier in drug development and so avoid failures in more advanced (Phase III) trials. By setting up a cohort of patients ready to enter trials and creating a pan-European network of trial sites, EPAD will also make clinical trials more efficient.

This interactive symposium will give you an opportunity to learn more about this exciting project and ask questions to some of the lead researchers involved in EPAD:

According to Simon Lovestone, Professor of translational Neuroscience at the University of Oxford “the long pre-clinical evolution of Alzheimer's disease presents an opportunity and a challenge; the opportunity being to treat the condition before it becomes clinically apparent the challenge being the enormous one of  performing practicable clinical trials in this early phase.”

Serge Van der Geyten, the EPAD Coordinator and Director, Neuroscience External Affairs at Janssen Research and Development will highlight the commitment and expectations of the pharmaceutical industry who sees the project as an opportunity to avoid the mistakes from the past, learn from each other and de-risk our compounds in a much faster and clearer way, hopefully bringing better, more effective drugs to patients faster.

Shirlene Badger, the lead of the EPAD work package on ethical, legal and social implications and senior researcher at the University of Cambridge, will show how social issues and the inclusion of participant voices are central to the project.  She will discuss key ethical questions with the audience.

This symposium is organised by EPAD, a project which has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.



Last Updated: Monday 28 September 2015


  • Acknowledgements

    The 25th AE Conference in Ljubljana received funding under an operating grant from the European Union’s Health Programme (2014-2020). Alzheimer Europe and Spominčica gratefully acknowledge the support of all conference sponsors.
  • European Union
  • Roche
  • SCA Global Hygiene